OncoMatch/Clinical Trials/NCT05796973

Measuring Oncological Value of Exercise and Statin

Is NCT05796973 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Atorvastatin for prostate cancer.

Phase 3RecruitingTampere University HospitalNCT05796973Data as of May 2026

Treatment: Atorvastatin — The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Breast Carcinoma

Renal Cell Carcinoma

Ovarian Cancer

Disease stage

Required: Stage III, IV

Metastatic disease required

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify